These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 32089218)

  • 21. Luspatercept in combination with recombinant erythropoietin in patients with myelodysplastic syndrome with ring sideroblasts: Stimulating early and late-stage erythropoiesis.
    Fattizzo B; Versino F; Bortolotti M; Rizzo L; Riva M; Barcellini W
    Eur J Haematol; 2023 May; 110(5):571-574. PubMed ID: 36727250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is luspatercept the new standard of care in transfusion-dependent low-risk myelodysplastic syndromes?
    Garcia-Manero G
    Clin Adv Hematol Oncol; 2024 Oct; 22(8):367-369. PubMed ID: 39356814
    [No Abstract]   [Full Text] [Related]  

  • 23. Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.
    Garcia-Manero G; Mufti GJ; Fenaux P; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Ilhan O; Sekeres MA; Zeidan AM; Ito R; Zhang J; Rampersad A; Sinsimer D; Backstrom JT; Platzbecker U; Komrokji RS
    Blood; 2022 Jan; 139(4):624-629. PubMed ID: 34758066
    [No Abstract]   [Full Text] [Related]  

  • 24. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis.
    Fenaux P; Kiladjian JJ; Platzbecker U
    Blood; 2019 Feb; 133(8):790-794. PubMed ID: 30602619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Smad2/3-pathway ligand trap luspatercept enhances erythroid differentiation in murine β-thalassaemia by increasing GATA-1 availability.
    Martinez PA; Li R; Ramanathan HN; Bhasin M; Pearsall RS; Kumar R; Suragani RNVS
    J Cell Mol Med; 2020 Jun; 24(11):6162-6177. PubMed ID: 32351032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Approaches for Anemia in MDS.
    Platzbecker U
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S59-S60. PubMed ID: 32862871
    [No Abstract]   [Full Text] [Related]  

  • 27. Bone marrow Tfr2 deletion improves the therapeutic efficacy of the activin-receptor ligand trap RAP-536 in β-thalassemic mice.
    Tanzi E; Di Modica SM; Bordini J; Olivari V; Pagani A; Furiosi V; Silvestri L; Campanella A; Nai A
    Am J Hematol; 2024 Jul; 99(7):1313-1325. PubMed ID: 38629683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes.
    Komrokji RS; Aguirre LE; Al Ali NH; Chan O; Xie Z; Kuykendall A; Sweet K; Lancet JE; Padron E; Sallman DA
    Blood Adv; 2023 Jul; 7(14):3677-3679. PubMed ID: 37058483
    [No Abstract]   [Full Text] [Related]  

  • 29. Lowering the boom on lower-risk myelodysplastic syndromes.
    Sekeres MA; Patel BJ
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):367-372. PubMed ID: 31808873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis.
    Suragani RN; Cadena SM; Cawley SM; Sako D; Mitchell D; Li R; Davies MV; Alexander MJ; Devine M; Loveday KS; Underwood KW; Grinberg AV; Quisel JD; Chopra R; Pearsall RS; Seehra J; Kumar R
    Nat Med; 2014 Apr; 20(4):408-14. PubMed ID: 24658078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population Pharmacokinetics and Exposure-Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes.
    Chen N; Kassir N; Laadem A; Maxwell SE; Sriraman P; Giuseppi AC; Ritland S; Linde PG; Budda B; Reynolds JG; Zhou S; Palmisano M
    CPT Pharmacometrics Syst Pharmacol; 2020 Jul; 9(7):395-404. PubMed ID: 32602651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough.
    Patnaik MM; Tefferi A
    Am J Hematol; 2023 Aug; 98(8):1171-1175. PubMed ID: 37345627
    [No Abstract]   [Full Text] [Related]  

  • 33. Therapy for lower-risk MDS.
    Carraway HE; Saygin C
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):426-433. PubMed ID: 33275714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Role of Iron in Benign and Malignant Hematopoiesis.
    Sinha S; Pereira-Reis J; Guerra A; Rivella S; Duarte D
    Antioxid Redox Signal; 2021 Aug; 35(6):415-432. PubMed ID: 33231101
    [No Abstract]   [Full Text] [Related]  

  • 35. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia.
    Suragani RN; Cawley SM; Li R; Wallner S; Alexander MJ; Mulivor AW; Gardenghi S; Rivella S; Grinberg AV; Pearsall RS; Kumar R
    Blood; 2014 Jun; 123(25):3864-72. PubMed ID: 24795345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
    Cappellini MD; Viprakasit V; Taher AT; Georgiev P; Kuo KHM; Coates T; Voskaridou E; Liew HK; Pazgal-Kobrowski I; Forni GL; Perrotta S; Khelif A; Lal A; Kattamis A; Vlachaki E; Origa R; Aydinok Y; Bejaoui M; Ho PJ; Chew LP; Bee PC; Lim SM; Lu MY; Tantiworawit A; Ganeva P; Gercheva L; Shah F; Neufeld EJ; Thompson A; Laadem A; Shetty JK; Zou J; Zhang J; Miteva D; Zinger T; Linde PG; Sherman ML; Hermine O; Porter J; Piga A;
    N Engl J Med; 2020 Mar; 382(13):1219-1231. PubMed ID: 32212518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetics and Exposure-Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β-Thalassemia.
    Chen N; Kassir N; Laadem A; Giuseppi AC; Shetty J; Maxwell SE; Sriraman P; Ritland S; Linde PG; Budda B; Reynolds JG; Zhou S; Palmisano M
    J Clin Pharmacol; 2021 Jan; 61(1):52-63. PubMed ID: 32696522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Luspatercept for the treatment of congenital sideroblastic anemia: Two case reports.
    Shao Y; He L; Ding S; Fu R
    Curr Res Transl Med; 2024 Mar; 72(1):103438. PubMed ID: 38244303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How we manage adults with myelodysplastic syndrome.
    Fenaux P; Platzbecker U; Ades L
    Br J Haematol; 2020 Jun; 189(6):1016-1027. PubMed ID: 31568568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.
    Platzbecker U; Götze KS; Kiewe P; Germing U; Mayer K; Radsak M; Wolff T; Chromik J; Sockel K; Oelschlägel U; Haase D; Illmer T; Al-Ali HK; Silling G; Reynolds JG; Zhang X; Attie KM; Shetty JK; Giagounidis A
    J Clin Oncol; 2022 Nov; 40(33):3800-3807. PubMed ID: 35998303
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.